|
시장보고서
상품코드
2102540
진행성 간암 시장 규모, 점유율, 성장 분석 : 암 유형별, 치료 유형별, 약물 계열별, 치료 라인별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Advanced Liver Cancer Market Size, Share, and Growth Analysis, By Cancer Type, By Treatment Type, By Drug Class, By Line of Therapy, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 진행성 간암 시장 규모는 2024년에 58억 4,000만 달러로 평가되었으며, 2025년 63억 3,000만 달러에서 2033년까지 120억 7,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 8.4%로 성장할 것으로 전망됩니다.
진행성 간암 시장에는 말기 간세포암 및 담관암을 대상으로 한 치료제, 생물학적 제제, 진단 도구가 포함됩니다. 간암은 전 세계적으로 암의 주요 사망 원인 중 하나일 뿐만 아니라, 효과적인 치료 옵션이 제한적이라는 점에서 이 분야는 매우 중요합니다. 주요 성장 요인으로는 B형 및 C형 간염 유병률의 상승과 더불어, 비만과 관련된 지방간 질환의 증가를 들 수 있습니다. 연간 신규 진단 건수가 급격히 증가하고 있으며, 이러한 우려스러운 추세에 따라 생명공학 기업들은 연구 개발 노력을 강화하고 있습니다. 최근 동향에 따르면 파이프라인이 확대되고 있는 것으로 나타났으며, 특히 주목할 만한 규제 당국의 승인 및 혁신적인 병용요법이 이 어려운 치료 환경에서 치료 프로토콜을 재구성하고 환자 치료 수준을 향상시키고 있습니다.
세계 진행성 간암 시장은 암 유형, 치료 유형, 약물 분류, 치료 단계, 투여 경로, 최종사용자 및 지역별로 구분됩니다. 암 유형에 따라 시장은 간세포암(HCC), 간내 담관암(ICC), 그리고 간세포암·담관암 복합형(cHCC-CCA)으로 분류됩니다. 치료법별로는 표적 치료, 면역 치료, 화학요법, 병용요법, 국소·영역 치료, 기타로 분류됩니다. 약제 분류별로는 티로신 키나제 억제제(TKI), 면역관문억제제, VEGF 억제제, 단일클론 항체, 기타로 분류됩니다. 치료 단계별로는 1차 치료, 2차 치료, 3차 및 그 이후 치료로 구분됩니다. 투여 경로별로는 경구 투여 및 정맥내 투여로 구분됩니다. 최종사용자별로는 병원, 전문 암 센터, 외래 수술 센터, 기타로 구분됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다.
세계 진행성 간암 시장의 성장요인
분자 표적 치료의 확대는 진행성 간암 치료 방식에 혁명을 일으켰으며, 의료 전문가들이 특정 종양 기전에 효과적으로 대처할 수 있게 했습니다. 이러한 혁신적인 치료법은 많은 경우 부작용을 줄이고 치료받는 환자의 내약성을 향상시키기 때문에 이러한 진보는 치료 전반의 유효성을 높이고 환자의 예후를 최적화합니다. 그 결과, 의료 종사자들은 이러한 첨단 치료 옵션에 대한 신뢰를 강화하고 있으며, 연구 투자가 확대됨에 따라 새로운 치료법이 확립된 치료 지침에 반영되는 것이 촉진되고 있습니다. 또한, 제약 회사 및 진단 기술 기업과의 협력도 증가하고 있는데, 이는 새로운 치료 기법이 확대되는 맞춤형 의료 트렌드와 부합하고 있음을 반영합니다.
세계 진행성 간암 시장의 제약요인
새로 승인된 표적 치료 및 면역 치료에 수반되는 고비용은, 특히 자원이 제한된 환경이나 개발도상국에서 의료 시스템 내 도입에 있어 큰 과제가 되고 있습니다. 이러한 고가의 구매 가격으로 인해 의료 제공자나 보험사는 종종 엄격한 환급 기준을 설정하고 있어, 대상 환자 집단 중 극히 일부만이 이러한 첨단 치료를 받을 수 있게 되었습니다. 이러한 재정적 제약으로 인해 의사가 최적의 치료법을 처방하는 데 방해가 되어 시장 침투가 지연될 뿐만 아니라, 다양한 유통 전략에 대한 잠재적 자금 투자도 저해되고 있습니다. 그 결과, 이러한 약제가 임상 지침에 반영되기까지 지연이 지속되어 환자 관리 및 치료 성과에 영향을 미치고 있습니다.
세계 진행성 간암 시장 동향
세계 진행성 간암 시장에서는 특히 치료 프로토콜에 체크포인트 억제제나 세포 치료법을 도입함으로써 면역요법의 통합을 향한 큰 변화가 나타나고 있습니다. 이러한 혁신적인 약제와 티로신 키나제 억제제를 병용하는 추세가 증가하고 있으며, 유효성 향상이 입증된 새로운 임상적 근거에 힘입어 종양 전문의들 사이에서 지지를 얻고 있습니다. 이러한 패러다임의 전환은 환자의 예후를 개선할 뿐만 아니라, 제약사들이 이러한 병용요법의 연구 개발을 우선시하도록 촉진하고 있습니다. 그 결과, 시장은 상당한 성장이 예상되며, 이는 진행성 간암의 치료 옵션을 발전시키려는 노력을 반영하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 진행성 간암 시장 규모 : 암 종류별
세계의 진행성 간암 시장 규모 : 치료 유형별
세계의 진행성 간암 시장 규모 : 약물 계열별
세계의 진행성 간암 시장 규모 : 치료 라인별
세계의 진행성 간암 시장 규모 : 투여 경로별
세계의 진행성 간암 시장 규모 : 최종사용자별
세계의 진행성 간암 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.11Global Advanced Liver Cancer Market size was valued at USD 5.84 Billion in 2024 and is poised to grow from USD 6.33 Billion in 2025 to USD 12.07 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).
The advanced liver cancer market encompasses therapeutics, biologics, and diagnostic tools targeting late-stage hepatocellular carcinoma and cholangiocarcinoma. This area is critical, as liver cancer stands as a leading cause of cancer globally, coupled with a limited array of effective treatment options. Key growth drivers include the rising prevalence of hepatitis B and C, along with obesity-related fatty liver disease. Annual diagnoses have surged significantly, reflecting an alarming trend that has prompted biotechnology firms to intensify their research and development efforts. Recent advancements showcase a growing pipeline, highlighted by notable regulatory approvals and innovative combination therapies that are reshaping treatment protocols and enhancing patient care standards in this challenging therapeutic landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Advanced Liver Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Advanced Liver Cancer Market Segments Analysis
The global advanced liver cancer market is segmented by cancer type, treatment type, drug class, line of therapy, route of administration, end user and region. Based on cancer type, the market is segmented into Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC) and Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA). Based on treatment type, the market is segmented into Targeted Therapy, Immunotherapy, Chemotherapy, Combination Therapy, Locoregional Therapy and Others. Based on drug class, the market is segmented into Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, VEGF Inhibitors, Monoclonal Antibodies and Others. Based on line of therapy, the market is segmented into First-Line Therapy, Second-Line Therapy and Third-Line and Later Therapy. Based on route of administration, the market is segmented into Oral and Intravenous. Based on end user, the market is segmented into Hospitals, Specialty Cancer Centers, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Advanced Liver Cancer Market
The expansion of targeted molecular therapies has revolutionized the approach to treating advanced liver cancer, enabling medical specialists to address specific tumor mechanisms effectively. This progress enhances overall treatment efficacy and optimizes patient outcomes, as these innovative therapies often result in reduced side effects and improved tolerability for individuals undergoing treatment. Consequently, healthcare providers are increasingly confident in these advanced options, leading to heightened investments in research and facilitating the integration of emerging therapies into established treatment guidelines. Furthermore, collaboration with pharmaceutical and diagnostic technology companies is on the rise, reflecting the alignment of new treatment methodologies with the growing trends in personalized medicine.
Restraints in the Global Advanced Liver Cancer Market
The high costs associated with newly approved targeted therapies and immunotherapies pose significant challenges for their adoption within healthcare systems, particularly in resource-constrained environments and developing nations. Due to these steep acquisition prices, providers and payers often implement stringent reimbursement criteria, limiting access to these advanced treatments for only a fraction of the eligible patient population. Such financial constraints hinder physicians from prescribing optimal therapies, resulting in a slower market penetration and deterring potential financial investments in varied distribution strategies. As a result, the integration of these drugs into clinical guidelines continues to face delays, affecting patient care and outcomes.
Market Trends of the Global Advanced Liver Cancer Market
The Global Advanced Liver Cancer market is witnessing a significant shift towards the integration of immunotherapy, particularly through the adoption of checkpoint inhibitors and cellular therapies in treatment protocols. The growing trend of combining these innovative agents with tyrosine kinase inhibitors is gaining traction among oncologists, driven by emerging clinical evidence that demonstrates enhanced efficacy. This paradigm shift not only leads to improved patient outcomes but also prompts pharmaceutical companies to prioritize the research and development of such combination therapies. As a result, the market is poised for substantial growth, reflecting a commitment to advancing treatment options for advanced liver cancer.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Advanced Liver Cancer Market Size by Cancer Type & CAGR (2026-2033)
- Market Overview
- Hepatocellular Carcinoma (HCC)
- Intrahepatic Cholangiocarcinoma (ICC)
- Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA)
Global Advanced Liver Cancer Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Combination Therapy
- Locoregional Therapy
- Others
Global Advanced Liver Cancer Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Tyrosine Kinase Inhibitors (TKIs)
- Immune Checkpoint Inhibitors
- VEGF Inhibitors
- Monoclonal Antibodies
- Others
Global Advanced Liver Cancer Market Size by Line of Therapy & CAGR (2026-2033)
- Market Overview
- First-Line Therapy
- Second-Line Therapy
- Third-Line and Later Therapy
Global Advanced Liver Cancer Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Intravenous
Global Advanced Liver Cancer Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Cancer Centers
- Ambulatory Surgical Centers
- Others
Global Advanced Liver Cancer Market Size & CAGR (2026-2033)
- North America (Cancer Type, Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User)
- US
- Canada
- Europe (Cancer Type, Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Cancer Type, Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Cancer Type, Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Cancer Type, Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirtex Medical US LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boston Scientific Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
